Basic Provera Information

• INN (International Nonproprietary Name): Medroxyprogesterone Acetate
• Brand Names Available In Canada (English): Provera (various generics) as tablets; Depo-Provera and Depo-SubQ Provera 104 appear in global injectable listings and are the injectable depot formulations referenced in Canada and internationally.
• ATC Code: G03DA02
• Forms & Dosages: Oral tablets 2.5 mg, 5 mg, 10 mg in bottles of 30, 100, 500; injectable depot forms with 104 mg (Depo-SubQ Provera 104) and 150 mg/mL (Depo-Provera 150 mg/mL) in vials or prefilled syringes.
• Manufacturers In Canada (English): Not specified
• Registration Status In Canada (English): Provera is listed as available in Europe and Canada as various generics; specific Health Canada registration numbers are not specified in the provided data.
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Patients and clinicians ask whether Depo-Provera still performs as expected in real life.

Recent research between 2022 and 2025 highlights three consistent messages about medroxyprogesterone acetate (MPA).

First, injectable MPA remains highly effective as 3-month contraception with Depo-Provera 150 mg IM and Depo-SubQ Provera 104 mg SQ providing sustained contraception for roughly 12–13 weeks.

Second, short-course oral MPA at 5–10 mg shows effectiveness for treating abnormal uterine bleeding and for endometrial protection when used with estrogen in HRT regimens.

Third, bone mineral density (BMD) decline with long-term injectable use remains the most notable safety signal prompting reassessment if use extends beyond two years.

Main Outcomes

Effectiveness for contraception with depot injections continues to be high when injections are given every 12–13 weeks.

Oral medroxyprogesterone acetate in low doses is effective for short-term control of bleeding and for cyclical endometrial protection alongside estrogen therapy.

Recent Canadian cohort analyses emphasise continuation rates, real-world side-effect profiles and the importance of equitable access, especially in rural and Indigenous communities.

Safety Observations

Post-market surveillance from 2022–2024 indicated thromboembolic events are rare but remain an absolute contraindication in people with active thromboembolic disease or breast malignancy.

Data consistently show reversible declines in bone mineral density with prolonged use of injectable Depo formulations, which underpins recommendations to reassess use after two years.

Overall, pharmacovigilance and cohort data are the strongest evidence available for these safety signals in this recent period, rather than new large randomised controlled trials.

Clinical Mechanism Of Action

Layman’s Explanation

People often ask how Provera works and why the tablet and injection can feel so different.

Medroxyprogesterone acetate acts like the body's natural progesterone.

Taken as a tablet it regulates the uterine lining to stop abnormal bleeding.

Given as an injection in depot form it suppresses ovulation and prevents pregnancy for about 12 to 13 weeks per dose.

Scientific Breakdown

Medroxyprogesterone acetate is a synthetic progestogen classified under ATC G03DA02.

It binds progesterone receptors in the hypothalamus, pituitary and endometrium to exert its effects.

Receptor Pharmacology

MPA exerts progestational effects through progesterone receptor activation, causing endometrial thinning and changes to cervical mucus.

At sustained high systemic levels—as with injectable depot formulations—MPA suppresses gonadotropin release and leads to anovulation.

Systemic Effects

Hepatic metabolism of MPA can modify sex-hormone binding and produce modest changes in lipids and glucose tolerance.

Depot formulations provide sustained plasma concentrations for approximately 12–13 weeks for each injection.

The mechanism explains common adverse effects such as menstrual irregularities, weight changes and mood shifts, and supports caution with long-term injectable use due to reversible BMD decline.

Scope Of Approved And Off-Label Use

Health Canada Approvals (DIN-Based)

Regulatory labels support oral and injectable forms of medroxyprogesterone acetate for menstrual disorders, abnormal uterine bleeding, endometrial protection during estrogen therapy, and injectable contraception.

Standard authorised regimens align with product monographs: oral tablets 5–10 mg for 5–10 days for abnormal uterine bleeding, 5–10 mg for 12–14 consecutive days per month for endometrial protection with estrogen, and injectables every three months (Depo-Provera 150 mg IM; Depo-SubQ Provera 104 mg SQ).

Products marketed in Canada carry DINs where listed and remain prescription-only.

Notable Off-Label Trends In Canadian Practice

Off-label use observed in Canadian clinical practice includes short-course MPA for endometriosis symptom control under specialist guidance.

Specialist teams may use MPA intermittently in transgender care as part of multi-disciplinary management plans.

MPA is also used for heavy menstrual bleeding when levonorgestrel IUDs or other progestogens are unsuitable.

Provincial formularies (Ontario Drug Benefit, BC PharmaCare, RAMQ) vary on coverage and may require documenting indication for reimbursement of injectables versus tablets.

Dosage Strategy

General Dosing Per Health Canada Monographs

Oral tablets are commonly prescribed at 5 or 10 mg once daily for 5–10 days for secondary amenorrhea or abnormal uterine bleeding.

For endometrial protection with estrogen, 5–10 mg daily for 12–14 days each month is the standard approach.

Injectable contraception follows a three-month schedule: Depo-Provera 150 mg IM every 3 months and Depo-SubQ 104 mg SQ every 3 months.

Typical counselling should reference the manufacturer syringe and vial specifications during administration.

Condition-Specific Dosing Adjustments

Liver impairment requires caution and specialist input because medroxyprogesterone acetate is hepatically metabolised.

Elderly patients do not usually require routine dose adjustment, but monitoring is advised for thromboembolic and cognitive risk factors.

Missed-dose instructions: for tablets, take the missed dose if remembered the same day; otherwise skip and do not double up.

For missed injections, administer as soon as possible and consider backup contraception per monograph guidance.

Pediatric use is limited and must be individualised by a specialist.

Injectable contraception should be reviewed if use extends beyond two years because of bone density considerations.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include known hypersensitivity to medroxyprogesterone acetate or excipients.

Active or prior thromboembolic disorders such as deep vein thrombosis, pulmonary embolism or stroke are contraindications.

Diagnosed or suspected breast or genital malignancy, undiagnosed vaginal bleeding, significant liver dysfunction and pregnancy are also absolute contraindications.

Adverse Effects (Post-Market Reports)

Common side effects reported in post-market surveillance include menstrual irregularities, weight change, headaches and breast tenderness.

Patients may experience bloating, nausea, mood changes and, for injectable forms, injection-site reactions.

Long-term depot use has the clearest safety concern: reversible decreases in bone mineral density during prolonged use.

Healthcare providers should assess fracture risk, counsel on calcium and vitamin D, and discuss smoking cessation and alternative contraceptive options if extended use is anticipated.

Interaction Mapping

Food Interactions Common In Canadian Diet

No major food interactions of clinical significance are reported for oral medroxyprogesterone acetate.

Typical Canadian meals, including dairy or higher-fat foods, do not require timing adjustments for oral tablets.

Drug Combinations Flagged By Health Canada

Hepatic enzyme inducers can lower systemic progestogen levels and may reduce efficacy.

Strong CYP3A4 inducers such as some antiepileptic drugs and rifampin are specifically cautioned against when reliable contraception is required.

Herbal products like St John’s wort may also reduce hormonal levels and should be disclosed to the pharmacist.

Concurrent use with anticoagulants, glucose-lowering drugs and agents affecting mood warrants monitoring because MPA can modestly affect glucose tolerance and mood.

Patient Experience Analysis

Canadian Survey Data

Surveys and pharmacy records highlight a pattern: high satisfaction with contraceptive effectiveness and convenience for depot injections, but frequent concern about menstrual changes and perceived weight gain.

Community pharmacy data show many people discontinue Depo-Provera within 12 months, commonly due to irregular bleeding or weight concerns.

Concerns around delayed return-to-fertility are common in online forums, and clinical data confirm fertility usually returns, although delay may occur after the last injection.

Forum & Community Pharmacy Trends

Community pharmacists report counselling needs focused on bone health and on alternatives such as levonorgestrel IUDs and oral progestins.

Rural and Indigenous communities face access challenges because injectable contraception typically requires clinic visits while tablets can be dispensed from local pharmacies or via telepharmacy services.

Pharmacies in national chains and independents document reminder services for three-month injections and frequent requests for information on side effects and switching options.

Distribution And Pricing Landscape

National Pharmacy Chains

Provera tablets and generic medroxyprogesterone products are stocked across major Canadian chains including Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs.

Injectable Depo formulations are supplied to clinics and pharmacies that provide administration services rather than sold for home self-injection in most settings.

Online Pharmacy Availability & Provincial Restrictions

Tablets are widely available through licensed Canadian online pharmacies with prescription upload workflows, while injectables are restricted to clinical administration.

Provincial formularies differ on coverage; injectables often require prescriber documentation to access reimbursement through programs such as Ontario Drug Benefit, BC PharmaCare and RAMQ.

In our online pharmacy, provera is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-Border US Comparisons

List prices in some US markets may be lower, but cross-border purchases can lack Canadian DIN protection and pose regulatory and safety concerns.

Canadians are advised to use Canadian-licensed pharmacies for regulatory protections and bilingual labelling where required.

Alternative Options

Comparison Table Of DIN-Approved Alternatives

Pros And Cons Checklist

• Oral MPA: Cost-effective and easy to stop; may cause irregular bleeding.
• Injectable Depo-Provera: High adherence and convenience; possible delayed fertility return and BMD concerns with long-term use.
• LNG-IUD: Strong local bleeding control with minimal systemic effects; requires insertion and has differing provincial coverage.

Regulatory Status

Health Canada Approval Process

Health Canada authorises medications after reviewing quality, safety and efficacy data submitted by sponsors.

Approved MPA products receive a Drug Identification Number (DIN) to enable sale and formulary listing.

DIN And Bilingual Labelling Rules

Products marketed in Canada must meet Good Manufacturing Practice standards and provide bilingual English/French labelling and patient leaflets.

Provera formulations are prescription-only and are subject to post-market adverse reaction reporting to the Canada Vigilance Program.

Consolidated FAQ

Q: Will Depo-Provera affect my long-term fertility?

A: Fertility generally returns after stopping, although time to conception may be delayed for several months after the last 3-month injection.

Q: Is bone loss permanent?

A: Bone mineral density declines during long-term injectable use can be partially or fully reversible after stopping; assess fracture risk if using beyond two years and consider supplements and lifestyle measures.

Q: Can I take Provera with my antidepressant?

A: MPA can affect mood; most SSRIs do not have direct pharmacokinetic interactions but monitoring and consultation with the prescriber are advised.

Q: Are tablets available without a prescription?

A: No—Provera is prescription-only in Canada and must be dispensed by a licensed pharmacy with a valid prescription.

Q: What if I miss an injection?

A: Get the injection as soon as possible and follow product monograph guidance on backup contraception depending on timing and sexual activity.

Visual Guide

Patients and clinics benefit from clear visuals when choosing or counselling about MPA.

• Dosage Flowchart: Compare tablet regimens (5–10 mg short course; 12–14 days/month for HRT) and injectable schedules (Depo-Provera 150 mg IM every 12–13 weeks; Depo-SubQ 104 mg SQ every 12–13 weeks).
• Provincial Coverage Map: Highlight differences in Ontario Drug Benefit, BC PharmaCare and RAMQ for tablets versus clinic-administered injectables and special authorisation steps.
• Purchase Channels Infographic: Prescriber → community pharmacy chains (Shoppers, Rexall, London Drugs, Jean Coutu) for tablets; clinic-based administration for injectables; telepharmacy workflows for refills.
• Safety Icons: Contraindications (thromboembolism, breast cancer), BMD warning for >2-year injectable use, and storage guidance (tablets ≤25–30°C; injectables 15–30°C).

Storage And Transport

Canadian Household Guidelines

Store oral Provera tablets at or below 25–30°C in a dry place away from children and direct sunlight.

Avoid leaving tablets in hot vehicles during summer or in freezing conditions in winter.

Cold-Chain Storage Where Applicable

Injectable depots should be stored at 15–30°C, protected from light and not frozen.

Maintain cold-chain procedures during distribution and transit, especially for remote and northern supply chains supporting Indigenous communities.

Pharmacies and clinics must follow expiry and storage logs and provincial policies on handling and sharps disposal.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists confirm indication, screen for contraindications and review medication profiles before dispensing MPA tablets or arranging injectable appointments.

Counselling should cover expected menstrual changes, bone health considerations for injectable candidates and the time course for return to fertility after stopping injectables.

Reminder services and bridging contraception options are commonly offered by chain and independent pharmacies to reduce gaps in protection when injections are delayed.

Provincial Health Authority Guidance

Provincial health authorities recommend following Health Canada product monographs for missed doses and adverse event reporting to Canada Vigilance.

Clinicians should document indications for formulary coverage and consult local formularies for any special authorisation requirements.

Delivery Across Canada (English)

Closing Notes And Practical Counselling

If switching from another progestin, assess indication, bone health and thrombotic risk before initiating medroxyprogesterone acetate.

For contraception, ensure the patient understands timing for injections and backup contraception when doses are delayed.

For abnormal uterine bleeding, short courses of 5–10 mg oral MPA are effective and commonly used.

Report any suspected adverse reactions to Health Canada’s Canada Vigilance Program as part of routine safety practice.

When in doubt, consult the product monograph for exact dosing, missed-dose instructions and contraindications.

Available alternatives include norethindrone acetate, micronized progesterone and levonorgestrel options which should be discussed based on patient priorities such as bleeding control, systemic exposure and bone health.

Pharmacists and prescribers should document informed consent, especially when depot contraception use is likely to exceed two years, and should discuss mitigation strategies for bone health.